WAICF
15.12.2022 14:31:37 CET | Business Wire | Press release
On February 9th to 11th, 2023, the city of Cannes, in south of France, will once again become the world's nerve center for Artificial Intelligence (AI) during the World AI Cannes Festival, the first global event dedicated exclusively to AI, to the tech leaders who are innovating in it, and to the economic, human and societal issues that will impact our lives in the near future.
A second edition with a rich program
The Festival 2023 edition will be composed of several thematic zones, allowing to discover artificial intelligence in all its faces. Each zone will host companies and AI players introducing their solutions and offering demonstrations and immersive experiences. For the second edition, the thematic zones will focus on the new applications of artificial intelligence in robotics, gaming, catering, sports and well-being.
This new edition will also see the attendance of some countries through international pavilions (Switzerland, Scandinavia, Italy, Korea, Israel, Canada). An opportunity for visitors to take a world tour of Artificial Intelligence and discover the startups that will disrupt the future of the Tech sector. The world's leading universities and the best researchers on Artificial Intelligence will also be present at the Festival.
First renowned speakers to be featured at WAICF 2023
With two months to go before its opening, the WAICF is announcing some of the first headliners among many national and international speakers, coming from professional circles, research or public authorities:
- Chad ARONSON, Global Head of Intelligent Automation COE, UBER,
- Divya DWIVEDI, Advocate, SUPREME COURT OF INDIA
- Oren ETZIONI, CEO, Allen Institute for AI,
- Lila IBRAHIM, Chief Operating Officer, DEEPMIND,
- Luc JULIA, Chief Scientific Officer, RENAULT,
- Yann LECUN, Vice-President and Chief AI Scientist, META AI,
- Alberto PRADO, Vice-President, Global Head of Digital & Partnership, R&D, UNILEVER
- Stuart RUSSEL, Professor of Computer Science and Michael H. Smith and Lotfi A. Zadeh Chair in Engineering, UNIVERSITY OF CALIFORNIA, BERKELEY
- Manuela VELOSO, Head, J. P. MORGAN CHASE AI RESEARCH
- Miriam VOGEL, President & CEO, EqualAI,
More than a hundred speakers are expected for this new edition with an overview of AI in all its diversity through 5 categories of conferences:
- AI FOR SOCIETY: understanding the benefits of artificial intelligence for society, the planet, and the challenges that lie ahead.
- AI TODAY AND TOMORROW: explore what AI can do today to imagine what future innovations will bring to society and organizations tomorrow.
- AI STRATEGY: gain key insights to improve your AI strategy and take your business to the next level.
- AI TECHNOLOGY: learn how to make the best use of different AI technologies and train your innovation mindset with high-level speakers.
- AI APPLICATIONS: get an overview of the advances AI can bring to organizations, with focuses on different industries.
Press accreditations
To apply for your accreditation for the WAICF, please contact the PR team at waicf@agence-profile.com.
About the WAICF
The World AI Cannes Festival was born out of the desire to bring together businesses and individuals in Artificial Intelligence. Through a rich and diverse line up, attendees are invited to discover and understand the many ways in which artificial intelligence impacts our daily lives. The World AI Cannes Festival also presents a unique opportunity for businesses to be exposed to innovative ideas, novel information, and new findings. Businesses will be called to showcase their knowledge and experiences as well as to network with leading industry players and decision makers.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221215005434/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom